Covaxin safe for children between 2-18 years

Bharat Biotech today announced that BBV152 (Covaxin), its whole-virion inactivated Covid-19 vaccine candidate, has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study.

Bharat Biotech had conducted phase II/III, open-label, and multicenter studies to evaluate the safety, reactogenicity, and immunogenicity of Covaxin in healthy children and adolescents in the 2-18 age group.

The clinical trials conducted in the paediatric population between June 2021 and September 2021 have shown robust safety, reactogenicity, and immunogenicity. The data was submitted to the Central Drugs Standard Control Organisation (CDSCO) in October 2021, and received emergency-use nod for children aged 12-18 from DCGI recently.

In the study, no serious adverse event was reported. 374 subjects reported either mild or moderate severity symptoms with 78.6 per cent getting resolved within one day. Pain at the injection site was the most commonly reported adverse event.

Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, “Covaxin’s clinical trial data from the paediatric population is very encouraging. Safety of the vaccine is critical for children and we are glad to share that Covaxin has now proven data for safety and immunogenicity in children. We have now achieved our goal of developing a safe and efficacious Covid-19 vaccine for adults and children. Vaccines are a great preventive tool; the power of vaccines can only be harnessed if used prophylactically.”

---

Next Story :

Now you can get latest stories from Indtoday on Telegram everyday. Click the link to subscribe.  Click to follow Indtoday Facebook page and Twitter and on Instagram. For all the latest Hyderabad News updates